Story · Medicine & Biotech

Tandem wins FDA clearance for tubeless automated insulin delivery system

4 outlets · first reported by Drug Delivery Business on · latest · 73 hours of coverage · 2 countries

The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.” (MedTech Dive)

Coverage, in order

  1. first Drug Delivery Business obscure peer-reviewed
    Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set

    The Mobi with tubed and tubeless options. [Image courtesy of Tandem Diabetes Care] Tandem Diabetes Care (Nasdaq: TNDM) has secured an FDA clearance for a tubeless version of its miniaturized automated insulin delivery system. The Tandem Mobi’s new cartridge and infusion set converts the pump into a…

  2. Medical Dialogues India obscure
    FDA Approves Tubeless Option for Tandem Mobi Insulin Pump

    The US FDA has approved a tubeless cartridge and infusion set for the Tandem Mobi insulin pump, offering users the flexibility to choose between tubed and tubeless insulin delivery. The system incorporates Control-IQ+ technology, which predicts glucose levels and automatically adjusts insulin…

  3. MedTech Dive indie
    Tandem wins FDA clearance for tubeless automated insulin delivery system

    The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.”

  4. MedTech Dive indie peer-reviewed
    MiniMed gets FDA nod for tubeless insulin pump

    MiniMed will go head to head with Tandem Diabetes Care as both companies debut their first tubeless pumps.

  5. FDA clears Tandem Diabetes insulin pump for tubeless insulin delivery

    Patients with a Tandem Mobi insulin pump will soon be able to choose between two wear options—tubed and tubeless—with the same device. Tubeless insulin delivery can last up to seven days.

  6. MiniMed claims quick FDA clearance for Fit patch pump

    The waterproof MiniMed Fit sports a wear time of 7 days. [Image courtesy of MiniMed] After submitting its patch pump for FDA review in late August, MiniMed (Nasdaq: MMED) has turned around a quick clearance for the Fit automated insulin delivery system. The Fit marks the company’s first tubeless…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.